Homepage Top Section2

The company has revealed the positive topline data from two phase III multicentre studies assessing Xolair to treat adults with CRSwNP who have not adequately responded to intranasal

As part of strategic collaboration and licence agreement, the partnership will offer first broadly-available imaging biomarker research tool to pharmaceutical companies and major academic centers carrying out research

Xeomin is claimed to be the first and only neurotoxin with this approved indication in the EU. It secured approval from the US Food and Drug Administration (FDA)

The Swiss pharma company is looking for a conditional marketing authorization (CMA) for idebenone for DMD patients who are not using glucocorticoids for the treatment of their respiratory

Lyrica could not show a statistically significant reduction in seizure frequency in comparison to placebo in the late-stage trial held in 219 patients aged between five and 65

Shingrix is a non-live and recombinant subunit adjuvanted vaccine, which will be administered intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus

Based in Copenhagen, Nuevolution shares its advanced discovery platform and programmes with pharmaceutical and biotechnology companies to develop novel medical treatment options for the patients. Amgen’s offer represents

The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting

The latest approval for Fragmin is for the blood thinner to be used for reducing symptomatic venous thromboembolism (VTE) in pediatric patients, aged one month and older. The